Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

NCT07636148 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Mark C Burgmans, MD PhD
Phase
Observational
Started
2026-07-01
Last updated
2026-09-01

Condition(s) studied

Liver Cancer (Primary and Metastatic)Lung Cancer (Diagnosis)Bone Cancer MetastaticBone Cancer TumorKidney TumorsRenal CancerHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (Kidney Cancer)Renal Cell Carcinoma (RCC)Musculoskeletal CancersMusculoskeletal TumorsBone TumorsLung Tumors

Study summary

This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.

During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.

No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years; * Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors; * Use of spectral angio-CT image guidance as part of standard care; * Written confirmed consent. Exclusion Criteria: * Patients who are declared incapacitated; * Patients suffering from psychic disorders that make a comprehensive judgement impossible.

Primary outcome measure(s)

  • Local tumor control — 6 months, 1 year, 2 years, 3 years
    Local tumor control at the treated site, assessed at 6 months, 1 year, 2 years, and 3 years after the procedure.

Trial sites (3)

FacilityCityRegionStatus
Hospices Civils de Lyon - Hôpital Édouard Herriot Lyon Auvergne-Rhône-Alpes Not Yet Recruiting
Assistance Publique Hopitaux de Paris - Hôpital Henri Mondor Créteil Île-de-France Region Not Yet Recruiting
Leiden University Medical Center Leiden South Holland Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07636148 on ClinicalTrials.gov ↗ ← All trials in the Netherlands